Market Overview

Seattle Genetics No Longer On Goldman Sachs' Sell List

Share:
Seattle Genetics No Longer On Goldman Sachs' Sell List

Seattle Genetics, Inc. (NASDAQ: SGEN) received a ratings bump from Goldman Sachs to Neutral from Sell after the brokerage revised its Adcetris U.S. sales estimates in 1L Hodgkin's lymphoma (HL) "to reflect greater market penetration per physician diligence."

"We model 40 percent penetration (vs. 19 percent prior) in 1L HL, which reflects significant uptake in Stage III–IV patients (~50 percent of the incident pool). This translates to $754 million in US peak sales (vs. $358 million prior) and may be conservative depending on the magnitude of treatment benefit (a large benefit may drive use in Stage I/II patients)," analyst Salveen Richter wrote in a note.

Related Link: Here's Why Seattle Genetics' Adcetris Is A $2 Billion Product

Adcetris' base business in Hodgkin's lymphoma (HL) faces competition from anti-PD-1s Bristol-Myers Squibb Co (NYSE: BMY)'s Opdivo and Merck & Co., Inc. (NYSE: MRK)'s Keytruda.

"The restrictive Opdivo label in HL mitigated the near-term threat from PD-1s and Adcetris/Opdivo combo data in 2L HL at the American Society of Hematology (ASH) meeting could serve as an incremental positive for SGEN," Richter added.

Richter also raised the price target to $47 from $30, while the shares closed Wednesday's trading at $54.06.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for SGEN

DateFirmActionFromTo
Oct 2018BarclaysMaintainsOverweightOverweight
Oct 2018BarclaysMaintainsOverweightOverweight
Sep 2018Leerink SwannInitiates Coverage OnOutperform

View More Analyst Ratings for SGEN
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Upgrades Health Care Price Target Analyst Ratings Movers Best of Benzinga

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!

Preorders Suggest Apple's iPhone 7 May Exceed The Street's Low Expectations

Could The Internal Combustion Engine Lose Dominance To Electric Vehicles? Ford Thinks So